COLUMBIAUNIVERSITY-AAAT8639
Phase I/II
OPEN TO ACCRUAL
An Open-label Phase I/II Trial of Venetoclax-Dexamethasone in Relapsed and/or Refractory t(11;14) Systemic Light-Chain Amyloidosis
SWOG-S2213
Phase III
OPEN TO ACCRUAL
A Phase III, Randomized Study of Daratumumab, Cyclophosphamide, Bortezomib and Dexamethasone (Dara-VCD) Induction Followed by Autologous Stem Cell Transplant or Dara-VCD Consolidation and Daratumumab Maintenance in Patients with Newly Diagnosed AL Amyloidosis
WEILLCORNELL-AMY2006-DPD
Phase II
OPEN TO ACCRUAL
Daratumumab, Pomalidomide and Dexamethasone (DPd) in Relapsed/Refractory Light Chain Amyloidosis Patients Previously Exposed to Daratumumab